U of G Researchers Find New Antifungal Resistance Target
Scientists Discover Key to Reversing antifungal Drug Resistance
Table of Contents
University of Guelph researchers have identified a protein that, when targeted, can restore the effectiveness of a crucial antifungal medication against a deadly fungus.
In a important breakthrough published in Nature Communications, a team at the University of Guelph, led by PhD student Michael Woods adn M.Sc. graduate Arianne Bermas, has pinpointed a way to perhaps overcome resistance to fluconazole, a vital and affordable antifungal medication. Their research focused on Cryptococcus neoformans, a fungus notorious for causing cryptococcal meningitis.
The Threat of Cryptococcus neoformans
Cryptococcus neoformans is a particularly hazardous pathogen, responsible for cryptococcal meningitis, a severe brain infection that tragically claims the lives of approximately 110,000 people annually. This fungus is a major contributor to AIDS-related deaths worldwide, accounting for one in every five such fatalities. The infection is most prevalent in sub-Saharan Africa, where fluconazole is a cornerstone of treatment. however, the emergence of drug-resistant strains poses a growing threat to public health.
Unlocking the Secret to Reversing Resistance
To understand how C. neoformans develops resistance, the Guelph researchers meticulously compared drug-resistant and drug-responsive strains in their lab.This comparative analysis allowed them to identify key molecular changes within the fungal cells.
Their inquiry zeroed in on six proteins of particular interest. Among these, the protein ClpX emerged as a critical player, involved in numerous survival functions within the fungus. The team discovered that by either deleting the gene responsible for producing ClpX (clpX) or by blocking its activity with a chemical compound known as Compound 334, they could effectively restore the fungus’s susceptibility to fluconazole. This means that immune cells and even mice infected with the modified, resistant fungus could once again be successfully treated with the widely used antifungal.
A Promising Path Towards Better Treatments
The implications of this finding are substantial. Compound 334, in particular, shows immense promise as a potential future therapeutic agent. Building on this foundational work, Kerry woolnough, a PhD student in bioinformatics also working with Professor Geddes-McAlister, is now employing machine learning techniques. Her goal is to refine Compound 334, making it highly specific to targeting ClpX in fungal cells